Paradigm Biopharmaceuticals Ltd (PAR) — Cash Flow-to-Debt Ratio
Paradigm Biopharmaceuticals Ltd (PAR) has a Cash Flow-to-Debt Ratio of -1.15x as of December 2025, meaning its operating cash flow of AU$-19.65 Million could theoretically repay -1% of its total liabilities (AU$17.16 Million) in one year. Explore Paradigm Biopharmaceuticals Ltd long-term investment intensity to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Paradigm Biopharmaceuticals Ltd Cash Flow-to-Debt Ratio (2014–2025)
Historical debt coverage capacity for Paradigm Biopharmaceuticals Ltd across 12 annual periods. Also explore PAR total asset value for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Paradigm Biopharmaceuticals Ltd (2014–2025)
Year-by-year debt coverage analysis for Paradigm Biopharmaceuticals Ltd. For market capitalisation and broader financial context, see PAR market cap overview.
| Year | CF-to-Debt Ratio | Operating CF (AUD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -4.72x | AU$-15.99 Million | AU$3.39 Million | ▲ +74.3% |
| 2024 | -18.40x | AU$-65.94 Million | AU$3.58 Million | ▼ -445.3% |
| 2023 | -3.37x | AU$-45.19 Million | AU$13.39 Million | ▲ +12.2% |
| 2022 | -3.84x | AU$-32.21 Million | AU$8.38 Million | ▲ +28.2% |
| 2021 | -5.36x | AU$-34.93 Million | AU$6.52 Million | ▼ -122.1% |
| 2020 | -2.41x | AU$-10.09 Million | AU$4.18 Million | ▼ -2.5% |
| 2019 | -2.35x | AU$-6.37 Million | AU$2.70 Million | ▲ +48.1% |
| 2018 | -4.53x | AU$-6.01 Million | AU$1.33 Million | ▲ +3.2% |
| 2017 | -4.68x | AU$-4.47 Million | AU$955.29K | ▼ -45.7% |
| 2016 | -3.21x | AU$-3.59 Million | AU$1.12 Million | ▼ -54.1% |
| 2015 | -2.08x | AU$-1.20 Million | AU$577.33K | ▼ -24.4% |
| 2014 | -1.68x | AU$-617.72K | AU$368.67K | — |